source
- Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipelineEli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
- Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startupVersant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…